Caribou Biosciences, Inc. (CRBU): Price and Financial Metrics

Caribou Biosciences, Inc. (CRBU): $1.72

0.00 (0.00%)

POWR Rating

Component Grades








Add CRBU to Watchlist
Sign Up

Industry: Biotech




#299 of 347

in industry

CRBU Price/Volume Stats

Current price $1.72 52-week high $8.59
Prev. close $1.72 52-week low $1.60
Day low $1.67 Volume 8,386,100
Day high $1.79 Avg. volume 1,997,160
50-day MA $3.12 Dividend yield N/A
200-day MA $4.89 Market Cap 155.35M

CRBU Stock Price Chart Interactive Chart >

Caribou Biosciences, Inc. (CRBU) Company Bio

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. Caribou Biosciences has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.

CRBU Latest News Stream

Event/Time News Detail
Loading, please wait...

CRBU Latest Social Stream

Loading social stream, please wait...

View Full CRBU Social Stream

Latest CRBU News From Around the Web

Below are the latest news stories about CARIBOU BIOSCIENCES INC that investors may wish to consider to help them evaluate CRBU as an investment opportunity.

3 Gene-Editing Stocks With the Potential to Mint Millionaires

Gene editing stocks are very likely to see a spike in demand over the coming weeks in the wake of FDA approval of CRISPR.

Alex Sirois on InvestorPlace | December 13, 2023

5 Things to Know Before The Stock Market Opens

The Federal Reserve will conclude its last policy meeting of the year with a decision to hold interest rates steady expected, and Tesla issued a recall over its Autopilot drive-assistance system. Here’s what investors need to know today.

Yahoo | December 13, 2023

Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024

-- Caribou met with the FDA and reached alignment on a pivotal trial in 2L LBCL with CB-010 versus a comparator arm of immunochemotherapy followed by HDCT and ASCT -- -- ANTLER Phase 1 trial continues dose expansion enrollment; initial dose expansion data and RP2D expected Q2 2024 -- -- Caribou plans to initiate Phase 3 pivotal trial by YE 2024 -- BERKELEY, Calif., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharma

Yahoo | December 12, 2023

Caribou Biosciences, Inc. (CRBU) Upgraded to Buy: What Does It Mean for the Stock?

Caribou Biosciences, Inc. (CRBU) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Yahoo | December 8, 2023

Next-Gen Biotech: 3 Companies Leading the Charge in Gene Therapy

These three gene therapy stocks should get huge boosts over the long term from the use of gene editing techniques to treat diseases.

Larry Ramer on InvestorPlace | December 7, 2023

Read More 'CRBU' Stories Here

CRBU Price Returns

1-mo -42.09%
3-mo -67.49%
6-mo -72.08%
1-year -60.28%
3-year N/A
5-year N/A
YTD -69.98%
2023 -8.76%
2022 -58.38%
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!